GTx, Inc. (GTXI)
A biopharmaceutical company dedicated to the discovery, development & commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis & bone loss, muscle wasting & other serious medical conditions.
Recs
It may not be fair, but the FDA wants data that GTX doesn't have. They don't have cash to do more trials. Sad story.
Recs
Company just took a big undesetrved hit. Current drugs are strong and good market share. Figure speculators took a bath on FDA issue and dumped all shares at any price. GTXI is cheap today
Recs
Playing a potential bounce.
Recs
buying into ZZ's argument that the bad news is "baked in"
Recs
These guys are toast
Recs
Glimmers of hope- meeting with the FDA to discuss future rulings, drug has technically not been rejected.
Recs
A harsh drop today on a Complete Response letter that includes a requirement for a new trial for the toremifiene 80mg dosage. But the bad news is now baked in, the company has more than a year of cash, and phase III data for toremifene 20mg in prostatic intraepithelial neoplasia is expected in early 2010. I wouldn't buy this in real but if disappointment and market weakness drag it below 4 I'll give it a serious look.
Recs
a bet on FDA approval of their new drug.
Recs
Pharma company with cancer trials. I bet against curing cancer even though that would be great.
Recs
Extremely High Price for Book Value
Recs
Decision from the FDA by 2/28/08. It would be the first approval of its kind so the stock should rally.
Recs
Promisng treatment for prostate cancer in late-stage development likely to fuel gains for GTXI over the next year or so.
Recs
s+p strong buy, reuters rated out-perform, target price $27
Recs
It has a couple of Phase lll trials going on. It is about ready to pop. Great short term possibilities and great long term too. It has good buzz in the market place. Several reports state it will have unbelievable growth when the products hit the market soon.
Recs
THERE ARE SEVERAL OPTIONS ON THE TABLE NOW. THERE WILL BE AN ANNOUCEMENT APRIL 12-15 CONCERNING THE FINAL TRAILS OF THEIR DRUGS
Recs
Speculative bet. I am a grad student and the concept of targeting nuclear receptors like estrogen receptor with compounds called SERMs (selective estrogen receptor modulators) is well established; I would predict if toxicology data are good (have to be if already in phase III), then these compounds will find off-label uses, that will over the years be added to the label. If someone who straddles both molecular understanding and industry experience can confirm this, then I would say that th is stock won't remain under the radar even before it starts to turn a solid profit. DISCLAIMER: Anyone investing in biotech knows, phase three is nowhere near a 10% guarantee that you've got something to sell, even a couple of years down the line. But I like the underlying science, and it's probably the sub-field I'll be working in for the rest of my career in pharma after getting hooded.
Recs
ready for the gate
Recs
has taken a beatin lately...but I am still in love with the pipeline.
Recs
great pipeline and collaborations with large pharmas
Recs
This drug is presently being tested for the treatment of prostrate cancer.Eight months ago it was tested on my friend along with a sugar pill the cancer is gone.I'm sure this drug is going to be around for a while.

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 22 1 2 Next »